Abstract: In the technical field of biomedicine, a bispecific antibody including (a) a first antibody that specifically binds to a first antigen or antigen binding fragment thereof; and (b) a second antibody that specifically binds to a second antigen or antigen binding fragment thereof. Specifically, the first antigen is B7H3 and the second antigen is NKP30, or the first antigen is NKP30 and the second antigen is B7H3.

Abstract: An anti-human TNFR2 antibody or antigen-binding fragment thereof and uses and pharmaceutical compositions thereof. The anti-human TNFR2 antibody or antigen-binding fragment thereof is capable of specifically binding to TNFR2, inhibiting Treg cell proliferation, and/or promoting effector Teff cell proliferation and activation.

Abstract: In the field of biomedicine, a heterodimeric protein and application thereof. The heterodimeric protein includes: (1) a light chain and a first heavy chain, where the light chain and the first heavy chain are combined to form a targeting moiety that exhibits binding specificity to a tumor antigen or an immune checkpoint, and the tumor antigen or the immune checkpoint includes B7H3; (2) a second heavy chain, wherein the second heavy chain includes a Fc region and an immunomodulator fused to the Fc region, and the immune regulator includes IL-10. The results of affinity test showed that the heterodimeric protein had high affinity for B7H3 and IL-10 receptors. The results of pharmacodynamic experiments in vivo showed that the heterodimeric protein had good anti-tumor activity.

Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of recognizing the first antigen, where the first antigen is a tumor-associated antigen (TAA); (b) a second antigen-binding portion, where the second antigen-binding portion is an innate immune cell agonist; and (c) a third antigen-binding portion capable of recognizing the third antigen, where the third antigen regulates the tumor microenvironment. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.

Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of recognizing the first antigen, where the first antigen is targeted to antigens associated with tumorigenesis or progression; (b) a second antigen-binding portion, where the second antigen-binding portion is an innate immune cell agonist; and (c) a third antigen-binding portion capable of recognizing the third antigen, where the third antigen regulates tumor microenvironment by regulating normal and abnormal angiogenesis. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.

Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of specifically recognizing the first antigen, where the first antigen is a tumor-associated antigen (TAA); (b) a second antigen-binding portion, where the second antigen-binding portion is an NK cell activator; and (c) a third functional portion, where the third functional portion includes a cytokine and/or a cytokine receptor. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.